

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

SCHEDULES

SCHEDULE 2

Section 2.

CONTROLLED DRUGS

PART I

CLASS A DRUGS

- 1 The following substances and products, namely:—
- [^{F1}(a)] Acetorphine.
[^{F2}Alfentanil.]
Allylprodine.
Alphacetylmethadol.
Alphameprodine.
Alphamethadol.
Alphaprodine.
Anileridine.
Benzethidine.
Benzylmorphine (3-benzylmorphine).
Betacetylmethadol.
Betameprodine.
Betamethadol.
Betaprodine.
Bezitramide.
Bufotenine.
^{F3} ...
^{F4} ...
[^{F5}Carfentanil.]
Clonitazene.
Coca leaf.
Cocaine.
Desomorphine.
Dextromoramide.
Diamorphine.
Diampromide.
Diethylthiambutene.
[^{F6}Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).]
Dihydrocodeinone *O*-carboxymethyloxime.

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

[^{F7}Dihydroetorphine]

Dimenoxadole.

Dimepheptanol.

Dimethylthiambutene.

Dioxaphetyl butyrate.

Diphenoxylate.

Dipipanone.

[^{F8}Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).]

Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine.

Ethylmethylthiambutene.

[^{F2}Eticyclidine.]

Etonitazene.

Etorphine.

Etoperidine.

[^{F9}Etryptamine]

Fentanyl.

Furethidine.

Hydrocodone.

Hydromorphanol.

Hydromorphone.

Hydroxypethidine.

Isomethadone.

Ketobemidone.

Levomethorphan.

Levomoramide.

Levophenacylmorphin.

Levorphanol.

[^{F5}Lofentanil]

Lysergamide.

Lysergide and other *N*-alkyl derivatives of lysergamide.

Mescaline.

Metazocine.

Methadone.

Methadyl acetate.

Methyldesorphine.

Methyldihydromorphine (6-methyldihydromorphine).

Metopon.

Morpheridine.

Morphine.

Morphine methobromide, morphine *N*-oxide and other pentavalent nitrogen morphine derivatives.

Myrophine.

^{F10}
...

Nicomorphine (3,6-dinicotinoylmorphine).

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Noracymethadol.
Norlevorphanol.
Normethadone.
Normorphine.
Norpipanone.
Opium, whether raw, prepared or medicinal.
Oxycodone.
Oxymorphone.
Pethidine.
Phenadoxone.
Phenampramide.
Phenazocine.
[^{F11}Phencyclidine.]
Phenomorphane.
Phenoperidine.
Piminodine.
Piritramide.
Poppy-straw and concentrate of poppy-straw.
Proheptazine.
Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid isopropyl ester).
Psilocin.
Racemethorphan.
Racemoramide.
Racemorphan.
[^{F12}Remifentanyl]
[^{F2}Rolicyclidine.]
[^{F13}Sufentanyl.]
[^{F2}Tenocyclidine.]
Thebacon.
Thebaine.
[^{F13}Tilidate.]
Trimeperidine.
[^{F14}4-Bromo-2,5-dimethoxy- α -methylphenethylamine].
4-Cyano-2-dimethylamino-4,4-diphenylbutane.
4-Cyano-1-methyl-4-phenyl-piperidine.
N,N-Diethyltryptamine.
N,N-Dimethyltryptamine.
2,5-Dimethoxy- α ,4-dimethylphenethylamine.
[^{F15}N-Hydroxy-tenamphetamine.]
1-Methyl-4-phenylpiperidine-4-carboxylic acid.
2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid.
[^{F16}4-Methyl-aminorex]
4-Phenylpiperidine-4-carboxylic acid ethyl ester.

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- [^{F17}(b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- [^{F18}(ba) the following phenethylamine derivatives, namely:—
- Allyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
 - 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol
 - 2-Amino-1-(3,4-dimethoxyphenyl)ethanol
 - Benzyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
 - 4-Bromo- *b* ,2,5-trimethoxyphenethylamine
 - N* -(4- *sec* -Butylthio-2,5-dimethoxyphenethyl)hydroxylamine
 - Cyclopropylmethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
 - 2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)ethylamine
 - 2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)-1-methylethylamine
 - 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
 - 2-(1,4-Dimethoxy-2-naphthyl)ethylamine
 - 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
 - N* -(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
 - 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
 - 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
 - a* , *a* -Dimethyl-3,4-methylenedioxyphenethylamine
 - a* , *a* -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
 - Dimethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
 - N* -(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
 - 4-Iodo-2,5-dimethoxy- *a* -methylphenethyl(dimethyl)amine
 - 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
 - 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
 - 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 - 2-Methoxyethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
 - 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
 - b* -Methoxy-3,4-methylenedioxyphenethylamine
 - 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
 - 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
 - 2-(*a* -Methyl-3,4-methylenedioxyphenethylamino)ethanol
 - a* -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
 - N* -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 - O* -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
 - a* -Methyl-4-(methylthio)phenethylamine
 - b* ,3,4,5-Tetramethoxyphenethylamine

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- b*, 2,5-Trimethoxy-4-methylphenethylamine;]
- (c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine an *N*-alkylphenethylamine, a-methylphenethylamine, an *N*-alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an *N*-alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents.]
- [^{F19}(d) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,
- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
 - (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
 - (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
 - (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
 - (vi) by replacement of the *N*-propionyl group by another acyl group;
- (e) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy-carbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an *N*-oxide or of a quaternary base.]

Textual Amendments

- F1** "(a)" inserted by [S.I. 1977/1243, art. 3\(a\)](#)
- F2** Word inserted by [S.I. 1984/859, art. 2\(2\)](#)
- F3** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\), art. 2\(2\)](#)
- F4** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\), art. 2\(2\)](#)
- F5** Word inserted by [S.I. 1986/2230, art. 2\(2\)\(a\)](#)
- F6** Word inserted by [S.I. 1975/421, art. 3](#)
- F7** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\), art. 2\(2\)\(a\)](#)
- F8** Word inserted by [S.I. 1973/771, art. 2](#)
- F9** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750, art. 2\(2\)](#)

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- F10** Words repealed by [S.I. 1973/771, art. 2](#)
F11 Word inserted by [S.I. 1979/299, art. 2](#)
F12 Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by The Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003 /1243), art. 2(2)(b)
F13 Word inserted by [S.I. 1983/765, art. 2\(a\)](#)
F14 Words inserted by [S.I. 1975/421, art. 3](#)
F15 Word inserted by [S.I. 1990/2589, art. 2\(a\)\(i\)](#)
F16 Word inserted by [S.I. 1990/2589, art. 2\(a\)\(ii\)](#)
F17 Sch. 2 Pt. I para. 1(b)(c) added by [S.I. 1977/1243, art. 3\(b\)](#)
F18 Sch. 2 Pt. I para. 1(ba) inserted (1.2.2002) by The Misuse of Drugs Act 1971 (Modification) Order 2001 (S.I. 2001/3932), [art. 2\(2\)](#)
F19 Sch. 2 Pt. I para. 1(d)(e) added by [S.I. 1986/2230, art. 2\(2\)\(b\)](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
- 3 Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [^{F20}not being a substance for the time being specified in Part II of this Schedule].

Textual Amendments

- F20** Words inserted by [S.I. 1973/771, art. 2](#)

- 4 Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
- 5 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.
- 6 Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.

PART II

CLASS B DRUGS

- 1 The following substances and products, namely:—
- [^{F21}(a)] Acetyldihydrocodeine.
 Amphetamine.
^{F22}
 ...
 Codeine.
^{F23}
 . . .
 Dihydrocodeine.
 Ethylmorphine (3-ethylmorphine).
 [^{F24}Glutethimide.]
 [^{F24}Lefetamine.]
 [^{F25}Mecloqualone.]
 [^{F25}Methaqualone.]

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

[^{F26}Methcathinone]
Methylamphetamine.
[^{F27}*α*-Methylphenethylhydroxylamine]
Methylphenidate.
[^{F25}Methylphenobarbitone.]
Nicocodine.
[^{F28}Nicodicodine (6-nicotinoyldihydrocodeine).]
Norcodeine.
[^{F29}Pentazocine.]
Phenmetrazine.
Pholcodine.
[^{F30}Propiram.]
[^{F26}Zipeprol]
[^{F21}(b) any 5,5 disubstituted barbituric acid.]

Textual Amendments

- F21** Sch. 2 Pt. 2 para. 1(b) added by [S.I. 1984/859, art. 2\(3\)](#)
F22 Words in Sch. 2 Pt. 2 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\)](#), art. 2(3)
F23 Word repealed by [S.I. 1985/1995, art. 2\(2\)\(a\)](#)
F24 Word inserted by [S.I. 1985/1995, art. 2\(2\)\(b\)](#)
F25 Word inserted by [S.I. 1984/859, art. 2\(3\)](#)
F26 Words in Sch. 2 Pt. 2 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750, art. 2\(3\)](#)
F27 Word in Sch. 2 Pt. 2 para. 1(a) inserted (1.2.2002) by [S.I. 2001/3932, art. 2\(3\)](#)
F28 Words inserted by [S.I. 1973/771, art. 2](#)
F29 Word inserted by [S.I. 1985/1995, art. 2\(2\)\(c\)](#)
F30 Word inserted by [S.I. 1973/771, art. 2](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule.
- 3 Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
- 4 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule, not being a preparation falling within paragraph 6 of Part I of this Schedule.

PART III

CLASS C DRUGS

- 1 The following substances, namely:—
- [^{F31}(a)] [^{F32}Alprazolam.]
[^{F33}Aminorex]
Benzphetamine.
[^{F32}Bromazepam.]

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

[^{F33}Brotizolam]
[^{F34}Buprenorphine]
[^{F32}Camazepam.]
[^{F35}Cannabinol]
[^{F35}Cannabinol derivatives]
[^{F35}Cannabis and cannabis resin]
[^{F36}Cathine.]
[^{F36}Cathinone.]
[^{F32}Chlordiazepoxide.]
Chlorphentermine.
[^{F32}Clobazam.]
[^{F32}Clorazepic acid.]
[^{F32}Clonazepam.]
[^{F32}Clotiazepam.]
[^{F32}Cloxazolam.]
[^{F32}Delorazepam.]
[^{F37}Dextropropoxyphene.]
[^{F32}Diazepam.]
[^{F38}Diethylpropion.]
[^{F32}Estazolam.]
[^{F32}Ethchlorvynol.]
[^{F32}Ethinamate.]
[^{F32}Ethyl loflazepate.]
[^{F36}Fencamfamin.]
[^{F36}Fenethylamine.]
[^{F36}Fenproporex.]
[^{F32}Fludiazepam.]
[^{F32}Flunitrazepam.]
[^{F32}Flurazepam.]
[^{F32}Halazepam.]
[^{F32}Haloxazolam.]
[^{F39}4-Hydroxy-n-butyric acid]
[^{F32}Ketazolam.]
[^{F32}Loprazolam.]
[^{F32}Lorazepam.]
[^{F32}Lormetazepam.]
[^{F32}Mazindol.]
[^{F32}Medazepam.]
[^{F36}Mefenorex.]
F40
. . .

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Mephentermine.
[^{F32}Meprobamate.]
[^{F33}Mesocarb]
F41
.
.
.
[^{F32}Methyprylone.]
[^{F42}Midazolam.]
[^{F32}Nimetazepam.]
[^{F32}Nitrazepam.]
[^{F32}Nordazepam.]
[^{F32}Oxazepam.]
[^{F32}Oxazolam.]
[^{F43}Pemoline.]
F40
.
.
.
Phendimetrazine.
[^{F32}Phentermine.]
[^{F32}Pinazepam.]
F40
.
.
.
Pipradrol.
[^{F32}Prazepam.]
F40
.
.
.
F44
.
.
.
[^{F36}Pyrovalerone.]
[^{F32}Temazepam.]
[^{F32}Tetrazepam.]
[^{F32}Triazolam.]
[^{F36}N-Ethylamphetamine.]
[^{F45}Zolpidem]
[^{F46}(b) [^{F47}4-Androstene-3, 17-dione]
[^{F47}5-Androstene-3, 17-diol]
Atamestane.
Bolandiol.
Bolasterone.
Bolazine.
Boldenone.
Bolenol.
Bolmantalate.
Calusterone.
4-Chloromethandienone.
Clostebol.
Drostanolone.
Enestebol.
Epitiostanol.

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

Ethyloestrenol.
 Fluoxymesterone.
 Formebolone.
 Furazabol.
 Mebolazine.
 Mepitiostane.
 Mesabolone.
 Mestanolone.
 Mesterolone.
 Methandienone.
 Methandriol.
 Methenolone.
 Methyltestosterone.
 Metribolone.
 Mibolerone.
 Nandrolone.
 [^{F48}19-Nor-4-Androstene-3, 17-dione]
 [^{F48}19-Nor-5-Androstene-3, 17-diol]
 Norboletone.
 Norclostebol.
 Norethandrolone.
 Ovandrotone.
 Oxabolone.
 Oxandrolone.
 Oxymesterone.
 Oxymetholone.
 Prasterone.
 Propetandrol.
 Quinbolone.
 Roxibolone.
 Silandrone.
 Stanolone.
 Stanozolol.
 Stenbolone.
 Testosterone.
 Thiomesterone.
 Trenbolone.

- (c) any compound (not being Trilostane or a compound for the time being specified in sub-paragraph (b) above) structurally derived from 17-hydroxyandrostane-3-one or from 17-hydroxyestrane-3-one by modification in any of the following ways, that is to say,
- (i) by further substitution at position 17 by a methyl or ethyl group;
 - (ii) by substitution to any extent at one or more of positions 1, 2, 4, 6, 7, 9, 11 or 16, but at no other position;

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- (iii) by unsaturation in the carbocyclic ring system to any extent, provided that there are no more than two ethylenic bonds in any one carbocyclic ring;
- (iv) by fusion of ring A with a heterocyclic system;
- (d) any substance which is an ester or ether (or, where more than one hydroxyl function is available, both an ester and an ether) of a substance specified in sub-paragraph (b) or described in sub-paragraph (c) above [^{F49}or of cannabinol or a cannabinol derivative] ;
- (e) Chorionic Gonadotrophin (HCG).
Clenbuterol.
Non-human chorionic gonadotrophin.
Somatotropin.
Somatrem.
Somatropin.]

Textual Amendments

- F31** "(a)" inserted (1.9.1996) by [S.I. 1996/1300](#), [art. 2\(2\)\(a\)](#)
- F32** Word inserted by [S.I. 1985/1995](#), [art. 2\(3\)](#)
- F33** Words in Sch. 2 Pt. 3 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750](#), [art. 2\(4\)](#)
- F34** Word inserted by [S.I. 1989/1340](#), [art. 2\(a\)](#)
- F35** Word in Sch. 2 Pt. 3 para. 1(a) inserted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\)](#), [art. 2\(4\)](#)
- F36** Word inserted by [S.I. 1986/2230](#), [art. 2\(3\)](#)
- F37** Word inserted by [S.I. 1983/765](#), [art. 2\(a\)](#)
- F38** Word inserted by [S.I. 1984/859](#), [art. 2\(4\)\(a\)](#)
- F39** Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [arts. 1, 2\(3\)\(a\)](#)
- F40** Words repealed by [S.I. 1973/771](#), [art. 2](#)
- F41** Word repealed by [S.I. 1984/859](#), [art. 2\(4\)\(a\)](#)
- F42** Word inserted by [S.I. 1990/2589](#), [art. 2\(b\)](#)
- F43** Word inserted by [S.I. 1989/1340](#), [art. 2\(b\)](#)
- F44** Word in Sch. 2 Pt. 3 para. 1 omitted (1.9.1995) by virtue of [S.I. 1995/1966](#), [art. 2](#)
- F45** Word in Sch. 2 Pt. 3 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [arts. 1, 2\(3\)\(b\)](#)
- F46** Sch. 2 Pt. 3 para. 1(b)-(e) added (1.9.1996) by [S.I. 1996/1300](#), [art. 2\(2\)\(b\)](#)
- F47** Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [arts. 1, 2\(4\)\(a\)](#)
- F48** Word in Sch. 2 Pt. 3 para. 1(b) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [arts. 1, 2\(4\)\(b\)](#)
- F49** Words in Sch. 2 Pt. 3 para. 1(d) inserted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\)](#), [art. 2\(5\)](#)

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 of this Part of this Schedule [^{F50}not being phenylpropanolamine.]

Textual Amendments

- F50** Words added by [S.I. 1986/2230](#), [art. 2\(4\)](#)

Status: Point in time view as at 29/01/2004.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2. (See end of Document for details)

- 3 Any salt of a substance for the time being specified in paragraph 1 or 2 of this Part of this Schedule.
- 4 Any preparation or other product containing a substance for the time being specified in any of paragraphs 1 to 3 of this Part of this Schedule.

PART IV

MEANING OF CERTAIN EXPRESSIONS USED IN THIS SCHEDULE

For the purposes of this Schedule the following expressions (which are not among those defined in section 37(1) of this Act) have the meanings hereby assigned to them respectively, that is to say—

“cannabinol derivatives” means the following substances, except where contained in cannabis or cannabis resin, namely tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives;

“coca leaf” means the leaf of any plant of the genus *Erythroxylon* from whose leaves cocaine can be extracted either directly or by chemical transformation;

“concentrate of poppy-straw” means the material produced when poppy-straw has entered into a process for the concentration of its alkaloids;

“medicinal opium” means raw opium which has undergone the process necessary to adapt it for medicinal use in accordance with the requirements of the British Pharmacopoeia, whether it is in the form of powder or is granulated or is in any other form, and whether it is or is not mixed with neutral substances;

“opium poppy” means the plant of the species *Papaver somniferum* L;

“poppy straw” means all parts, except the seeds, of the opium poppy, after mowing;

“raw opium” includes powdered or granulated opium but does not include medicinal opium.

Status:

Point in time view as at 29/01/2004.

Changes to legislation:

There are currently no known outstanding effects for the Misuse of Drugs Act 1971, SCHEDULE 2.